Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Gastrointestinal |  Hematology |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Prostate |  Renal |  Solid Tumors |

Breast

Gastrointestinal

Hematology

Leukemia

Lung

  • Atezolizumab in Extensive Stage Small Cell Lung Cancer
    A phase 3, randomized, double-blind, placebo-controlled study of Carboplatin Plus Etoposide with or without Atezolizumab (Anti-PD-L1 Antibody) in patients with untreated extensive stage small cell lung cancer
  • Nivolumab in Advanced NSCLC
    A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies
  • MPDL328A (Anti-PD-L1 Antibody) with Chemotherapy for Squamous Non-Small Cell Lung Cancer
    A phase 3 open-label, multicenter, randomized study evaluating the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) in combination with Carboplatin + Paclitaxel or MPDL3280A in combination with Carboplatin + NAB-Paclitaxel versus Carboplatin + NAB-Paclitaxel in chemotherapy naïve patients with stage IV squamous non-small cell lung caner
  • MPDL328A (Anti-PD-L1 Antibody) with Chemotherapy in Non-Squamous Non-Small Cell Lung Cancer
    A phase 3, open-label, randomized study of MPDL3280A (Anti-PD-L1 Antibody) in combination with Carboplatin + Paclitaxel with or without Bevacizumab compared with Carboplatin + Paclitaxel + Bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer

Lymphoma

Myelomas

Prostate

Renal

Solid Tumors